Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bret Hafen

Nurse Practitioner, Psychiatric/Mental Health Layton, UT Nurse Practitioner

NPI 1982060828 CMS profile 10491805

934 S Main St, Layton, UT 84041

Open in the dashboard

General payments

$380,936

1,340 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bret Hafen of Layton, UT is reported in the CMS Open Payments database as having received $380,936 across 1,340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $217,976 493
2024 General $116,914 414
2023 General $42,690 247
2022 General $1,927 102
2021 General $1,429 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bret Hafen
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Bret Hafen were reported at $217,976. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Bret Hafen Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,429 $166 $54–$482 $132
2022 $1,927 $195 $66–$559 $149
2023 $42,690 $233 $82–$673 $160
2024 $116,914 $236 $84–$688 $164
2025 $217,976 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $203,258 529 payments
  2. AbbVie, Inc. $76,288 285 payments
  3. Alkermes, Inc. $37,509 120 payments
  4. Janssen Pharmaceuticals, Inc $30,069 90 payments
  5. Otsuka America Pharmaceutical, Inc. $20,506 87 payments
  6. E.R. Squibb & Sons, L.L.C. $7,732 28 payments
  7. Janssen Scientific Affairs, LLC $1,756 6 payments
  8. Sunovion Pharmaceuticals Inc. $1,207 88 payments
  9. Vanda Pharmaceuticals Inc. $578 27 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $405 7 payments
  11. Other $1,628 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $290,644 206 payments
  2. Travel and Lodging $51,843 257 payments
  3. Food and Beverage $22,435 864 payments
  4. Consulting Fee $15,925 9 payments
  5. Education $89 4 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $108,582 209 payments
  2. CAPLYTA Psychiatry $94,676 320 payments
  3. VRAYLAR Neuroscience $46,408 190 payments
  4. LYBALVI Cns $34,794 107 payments
  5. LYBALVI Cns $34,534 103 payments
  6. LYBALVI Cns $34,521 102 payments
  7. LYBALVI Cns $34,521 102 payments
  8. INVEGA SUSTENNA $30,931 72 payments
  9. INVEGA TRINZA $29,345 36 payments
  10. VRAYLAR Neuroscience $28,732 93 payments
  11. Other $45,744 419 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,558

Median for Nurse Practitioner: 389

Drug cost

$674,390

Median for Nurse Practitioner: $21,885

Branded share of claims

27.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 79 $238,597
Invega Trinza Paliperidone Palmitate Brand 21 $193,398
Abilify Maintena Aripiprazole Brand 30 $81,715
Vraylar Cariprazine Hcl Brand 21 $39,434
Caplyta Lumateperone Tosylate Brand 15 $34,939
Vivitrol Naltrexone Microspheres Brand 14 $22,187
Lurasidone Hcl Generic 35 $10,529
Paliperidone Er Paliperidone Brand 13 $6,788
Belsomra Suvorexant Brand 14 $6,310
Lisdexamfetamine Dimesylate Generic 28 $5,348

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$4,095

Medicare's payments for the services billed

Medicare patients

23

Average age 51

Services billed

86

12 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 48%
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$79,684 15 —
VRAYLAR
$20,918 21 —
ABILIFY ASIMTUFII
$5,357 — —
ABILIFY MAINTENA
$5,325 30 —
REXULTI
$3,797 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record